Mirum Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Mirum Pharmaceuticals Inc share price today is $88.51, up -2.44%. The stock opened at $91.085 against the previous close of $90.72, with an intraday high of $91.41 and low of $87.03.

Mirum Pharmaceuticals Inc Share Price Chart

Mirum Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Mirum Pharmaceuticals Inc Share Price Performance

$88.51 -0.0244(-2.44%) MIRM at 23 Mar 2026 02:17 PM Biotechnology
Lowest Today 87.03
Highest Today 91.41
Today’s Open 91.085
Prev. Close 90.72
52 Week High 109.28
52 Week Low 36.88
Day’s Range: Low 87.03 High 91.41
52-Week Range: Low 36.88 High 109.28
1 day return -
1 Week return -4.34
1 month return -16.38
3 month return +9.17
6 month return +19.63
1 year return +88.3
3 year return +298.2
5 year return +347.97
10 year return -

Mirum Pharmaceuticals Inc Institutional Holdings

Frazier Life Sciences Management, L.P. 11.26

HHG PLC 8.28

BlackRock Inc 5.97

Vanguard Group Inc 4.30

Eventide Asset Management, LLC 3.47

Bvf Inc 2.48

Vanguard Total Stock Mkt Idx Inv 2.24

State Street Corp 2.23

Eventide Gilead N 2.17

T. Rowe Price Associates, Inc. 2.13

Novo A/S 2.09

Wellington Management Company LLP 2.05

TANG CAPITAL MANAGEMENT LLC 2.05

State Street® SPDR® S&P® Biotech ETF 2.02

Geode Capital Management, LLC 1.76

ClearBridge Advisors, LLC 1.66

iShares Russell 2000 ETF 1.65

D. E. Shaw & Co LP 1.57

Citadel Advisors Llc 1.39

Janus Henderson Triton D 1.32

Janus Henderson US SMID Cap Growth 1.32

Polar Capital Holdings PLC 1.32

Point72 Asset Management, L.P. 1.31

Eventide Healthcare & Life Sciences I 1.28

Rock Springs Capital Management LP 1.26

Polar Capital Biotech S Inc 1.24

Janus Henderson Global Life Sciences 1.13

Janus Henderson Global Life Sciences D 1.13

Morgan Stanley - Brokerage Accounts 1.11

BNP Paribas Arbitrage, SA 1.09

Janus Henderson Glb Life Scn I2 USD 1.01

Janus Global Life Science AUSD 0.98

ClearBridge Small Cap Growth 0.90

ClearBridge Small Cap Growth A 0.90

T. Rowe Price New Horizons 0.87

Janus Henderson Hrzn Biotec E2 USD 0.85

Vanguard Institutional Extnd Mkt Idx Tr 0.79

US Small-Cap Growth II Equity Comp 0.76

Janus Henderson US Small Cap Growth 0.76

Janus Henderson Venture D 0.76

Mirum Pharmaceuticals Inc Market Status

Strong Buy: 6

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Mirum Pharmaceuticals Inc Fundamentals

Market Cap 5340.84 M

PB Ratio 17.3917

PE Ratio 0.0

Enterprise Value 5410.32 M

Total Assets 842.81 M

Volume 2231722

Mirum Pharmaceuticals Inc Company Financials

Annual Revenue FY25:521312000 521.3M, FY24:336888000 336.9M, FY23:144726000 144.7M, FY22:77062000 77.1M, FY21:19138000 19.1M

Annual Profit FY25:421072000 421.1M, FY24:255245000 255.2M, FY23:118213000 118.2M, FY22:64688000 64.7M, FY21:17235000 17.2M

Annual Net worth FY25:-23363000 -23.4M, FY24:-87942000 -87.9M, FY23:-164187000 -164.2M, FY22:-135665000 -135.7M, FY21:-83988000 -84.0M

Quarterly Revenue Q4/2025:148932000 148.9M, Q3/2025:133010000 133.0M, Q2/2025:127785000 127.8M, Q1/2025:111585000 111.6M, Q3/2024:90377000 90.4M

Quarterly Profit Q4/2025:192931000 192.9M, Q3/2025:107473000 107.5M, Q2/2025:104364000 104.4M, Q1/2025:88567000 88.6M, Q3/2024:69571000 69.6M

Quarterly Net worth Q4/2025:-5730000 -5.7M, Q3/2025:2905000 2.9M, Q2/2025:-5861000 -5.9M, Q1/2025:-14677000 -14.7M, Q3/2024:-14235000 -14.2M

About Mirum Pharmaceuticals Inc & investment objective

Company Information Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organisation Biotechnology

Employees 369

Industry Biotechnology

CEO Mr. Christopher Peetz

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Mirum Pharmaceuticals Inc FAQs

What is the share price of Mirum Pharmaceuticals Inc today?

The current share price of Mirum Pharmaceuticals Inc is $88.51.

Can I buy Mirum Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Mirum Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Mirum Pharmaceuticals Inc shares in India?

You can easily invest in Mirum Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Mirum Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Mirum Pharmaceuticals Inc?

Mirum Pharmaceuticals Inc has a market cap of $5340.84 M.

In which sector does Mirum Pharmaceuticals Inc belong?

Mirum Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Mirum Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Mirum Pharmaceuticals Inc?

The PE ratio of Mirum Pharmaceuticals Inc is N/A and the PB ratio is 17.39.